Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.43 |
| ▸ | PREP | P48147 | 3/20 | 0.43 |
| ▸ | FAP | Q12884 | 3/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4533897 | 0.91 | DPP4 (0.50) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL4534956 | 0.85 | CHRNB4 (0.53) | DPP4ALDH1A1CHRNB2CHRNA4HCRTR1 | |
| SCHEMBL4535781 | 0.82 | ALDH1A1 (0.48) | ALDH1A1CHRNB2CHRNA4 | |
| SCHEMBL13574258 | 0.76 | LTA4H (0.44) | DPP4FFAR1LTA4HHCRTR1 | |
| SCHEMBL520556 | 0.76 | ALOX5AP (0.47) | DPP4ALDH1A1HTT | |
| SCHEMBL520557 | 0.76 | ALOX5AP (0.47) | DPP4ALDH1A1HTT | |
| SCHEMBL521653 | 0.76 | ALOX5AP (0.47) | DPP4ALDH1A1HTT | |
| SCHEMBL4517266 | 0.75 | FAAH (0.46) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL14569497 | 0.75 | DPP4 (0.52) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL3313710 | 0.74 | CHRNB4 (0.44) | FFAR1ALDH1A1LTA4HCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
| EP-1802608-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040526-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | DPP4 1993/4885PREP 380/4885FAP 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.